Skip Navigation


JAC Advance Access originally published online on May 29, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
52/1/89    most recent
dkg277v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (21)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Vaudaux, P.
Right arrow Articles by Schrenzel, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vaudaux, P.
Right arrow Articles by Schrenzel, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 52, 89-95
© 2003 The British Society for Antimicrobial Chemotherapy

Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus

Pierre Vaudaux*, Patrice Francois, Carmelo Bisognano, Dongmei Li, Daniel P. Lew and Jacques Schrenzel

Division of Infectious Diseases, Geneva University Hospital, CH-1211 Geneva 14, Switzerland

Received 8 January 203; returned 14 February 2003; revised 4 March 2003; accepted 6 April 2003

The therapeutic activity of daptomycin was compared with that of vancomycin in a rat model of subcutaneously implanted tissue cages chronically infected with strain Rev1, a spontaneous methicillin-susceptible revertant of the methicillin-resistant Staphylococcus aureus strain MRGR3, showing equivalent virulence to its parent. The MIC and MBC of daptomycin (in Mueller–Hinton broth supplemented with 50 mg/L Ca2+) or vancomycin for strain Rev1 were 1–2 and 2–4 or 1 and 2 mg/L, respectively. In vitro elimination of strain Rev1 in the presence of 50% tissue cage fluid was more rapid with daptomycin 4 mg/L compared with vancomycin. After 2 weeks of infection, viable counts of strain Rev1 averaged 6.49 log10 cfu/mL of tissue cage fluid (n = 87). Intraperitoneal administration of daptomycin 30 mg/kg once daily, or vancomycin 50 mg/kg twice daily, produced antibiotic levels continuously above MBC. After 7 days of therapy with daptomycin or vancomycin, mean ± S.E.M. counts of Rev1 decreased (P < 0.05) by 1.11 ± 0.25 (n = 28) or 0.80 ± 0.31 (n = 35) log10 cfu/mL, respectively, compared with cages of untreated animals, but were not significantly different from each other. In daptomycin-treated rats, three cages yielded subpopulations with reduced susceptibility to daptomycin. In conclusion, a low dose regimen of daptomycin was at least equivalent to vancomycin against chronic foreign body infections due to S. aureus. Drug dosage should be adapted to obtain inflammatory fluid levels of daptomycin minimizing emergence of resistant subpopulations.

Keywords: Gram-positive bacteria, chronic infections, antimicrobial agents

* Corresponding author. Tel: +41-22-37-29-826. Fax: +41-22-37-29-830; E-mail: pierre.vaudaux@hcuge.ch


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
O. Murillo, C. Garrigos, M. E. Pachon, G. Euba, R. Verdaguer, C. Cabellos, J. Cabo, F. Gudiol, and J. Ariza
Efficacy of High Doses of Daptomycin versus Alternative Therapies against Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureus
Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4252 - 4257.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P. Vaudaux, B. Fleury, A. Gjinovci, E. Huggler, M. Tangomo-Bento, and D. P. Lew
Comparison of Tigecycline and Vancomycin for Treatment of Experimental Foreign-Body Infection Due to Methicillin-Resistant Staphylococcus aureus
Antimicrob. Agents Chemother., July 1, 2009; 53(7): 3150 - 3152.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. M. Traczewski, B. D. Katz, J. N. Steenbergen, and S. D. Brown
Inhibitory and Bactericidal Activities of Daptomycin, Vancomycin, and Teicoplanin against Methicillin-Resistant Staphylococcus aureus Isolates Collected from 1985 to 2007
Antimicrob. Agents Chemother., May 1, 2009; 53(5): 1735 - 1738.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
P. M. Hawkey
Pre-clinical experience with daptomycin
J. Antimicrob. Chemother., November 1, 2008; 62(suppl_3): iii7 - iii14.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
K. L. LaPlante and L. A. Mermel
In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model
Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2239 - 2246.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. S. Rouse, K. E. Piper, M. Jacobson, D. J. Jacofsky, J. M. Steckelberg, and R. Patel
Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis
J. Antimicrob. Chemother., February 1, 2006; 57(2): 301 - 305.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
I. I. Raad, H. A. Hanna, M. Boktour, G. Chaiban, R. Y. Hachem, T. Dvorak, R. Lewis, and B. E. Murray
Vancomycin-Resistant Enterococcus faecium: Catheter Colonization, esp Gene, and Decreased Susceptibility to Antibiotics in Biofilm
Antimicrob. Agents Chemother., December 1, 2005; 49(12): 5046 - 5050.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P. Vaudaux, A. Gjinovci, M. Bento, D. Li, J. Schrenzel, and D. P. Lew
Intensive Therapy with Ceftobiprole Medocaril of Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureus
Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3789 - 3793.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
C. A. Schriever, C. Fernandez, K. A. Rodvold, and L. H. Danziger
Daptomycin: A novel cyclic lipopeptide antimicrobial
Am. J. Health Syst. Pharm., June 1, 2005; 62(11): 1145 - 1158.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. N. Steenbergen, J. Alder, G. M. Thorne, and F. P. Tally
Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections
J. Antimicrob. Chemother., March 1, 2005; 55(3): 283 - 288.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.